LACTOLOGY FOUNDATION

Classification of Antitumor Drugs

Antitumor (anticancer) drugs are a heterogeneous group of agents that interfere with DNA synthesis and function, cell division, or key signaling pathways required for tumor growth and survival. They usually affect rapidly dividing cells, which explains both their therapeutic effect and many of their adverse reactions. From a lactation perspective, most classical cytotoxic agents are considered incompatible with breastfeeding because of their narrow therapeutic index, potential for serious toxicity in the infant, and long or unpredictable elimination.

Alkylating Agents

Mechanism of action
Alkylating agents bind directly to DNA, causing cross-links between strands or strand breaks, and thereby prevent DNA replication and transcription. They act predominantly on dividing cells, but can also damage resting cells to some extent.

Examples

• Cyclophosphamide: A prodrug activated in the liver, with a broad spectrum of use (lymphomas, solid tumors, conditioning in transplantation).
• Cisplatin: A platinum-containing compound, particularly effective in testicular, ovarian, head and neck, and lung cancers; it is a potent emetogenic agent and is notably nephrotoxic.

Major adverse effects
Typical class toxicities include myelosuppression (most frequent), alopecia, gastrointestinal adverse effects (nausea, vomiting), infertility, teratogenicity, nephrotoxicity (especially with cisplatin), pulmonary fibrosis (e.g. busulfan), and an increased risk of secondary malignancies.

Main contraindications
These include severe pre-existing myelosuppression, significant renal or hepatic failure (drug-specific), pregnancy, breastfeeding, and known hypersensitivity to the agent.

Lactation considerations
Alkylating agents generally pose a high risk during breastfeeding because they can reach the infant via milk and have the potential to cause profound bone marrow suppression, immunosuppression, and possible carcinogenic effects in the child. In clinical practice, breastfeeding is usually contraindicated during treatment and for a variable washout period afterward, depending on the agent’s half-life and cumulative toxicity. Any decision on resuming lactation should be individualized, often in consultation with oncology and lactation specialists and using up-to-date drug-specific data.

Antimetabolites

Mechanism of action
Antimetabolites are structurally similar to normal cellular metabolites such as purines, pyrimidines, or folates. They are incorporated into DNA or RNA or inhibit key enzymes (e.g. dihydrofolate reductase), thereby blocking nucleic acid synthesis and cell division.

Examples

• Methotrexate: A folate antagonist that inhibits dihydrofolate reductase, used for curative treatment of certain malignancies (e.g. choriocarcinoma), leukemias, lymphomas, solid tumors, and at lower doses for autoimmune diseases.
• 5-Fluorouracil (5-FU): A pyrimidine analog that inhibits thymidylate synthase and is incorporated into RNA; commonly used in colorectal, gastric, pancreatic, and breast cancers.

Major adverse effects
Frequent toxicities include myelosuppression, mucositis (oral and gastrointestinal), alopecia, gastrointestinal disturbances, hepatotoxicity (notably with methotrexate), neurotoxicity (e.g. high-dose cytarabine), and hand-foot syndrome with 5‑FU.

Main contraindications
Severe myelosuppression, severe renal or hepatic insufficiency (especially relevant for methotrexate), pregnancy, breastfeeding, hypersensitivity, and active infections are typical contraindications.

Lactation considerations
Methotrexate and most classical antimetabolites are considered incompatible with breastfeeding, especially at oncologic doses, because even small exposures can be toxic to rapidly dividing tissues in the infant. Short low-dose regimens (e.g. for autoimmune disease) may require nuanced, case-by-case risk assessment, but oncology doses normally mandate complete interruption of breastfeeding with appropriate milk suppression or storage strategies. For continuous infusions of 5‑FU, the sustained exposure further supports avoiding breastfeeding until the drug is fully cleared.

Antitumor Antibiotics

Mechanism of action
Most antitumor antibiotics inhibit topoisomerase II or intercalate into DNA, disrupting replication and transcription. Some generate free radicals that cause DNA strand breaks; they are not classical anti-infective antibiotics.

Examples

• Doxorubicin: An anthracycline that intercalates into DNA, inhibits topoisomerase II, and generates free radicals; it has a broad antitumor spectrum (breast cancer, sarcomas, lymphomas, leukemias) and is associated with dose-dependent cardiotoxicity.
• Bleomycin: Generates free radicals leading to DNA strand breaks; it causes little myelosuppression and is important in testicular carcinomas and Hodgkin lymphoma, but has significant pulmonary toxicity and risk of fibrosis.

Major adverse effects
Common adverse effects include myelosuppression (less pronounced with bleomycin), alopecia, gastrointestinal disturbances, stomatitis, cardiotoxicity (anthracyclines), pulmonary toxicity (bleomycin), skin and nail changes, and radiation recall reactions.

Main contraindications
Severe myelosuppression (less relevant for bleomycin), existing heart failure or cardiomyopathy (anthracyclines), pre-existing lung disease (bleomycin), pregnancy, breastfeeding, and hypersensitivity are major contraindications.

Lactation considerations
Anthracyclines such as doxorubicin have long half-lives, large volumes of distribution, and serious potential for cardiotoxicity, making them particularly problematic in the breastfeeding context. Given the risk of cumulative cardiotoxic effects and immunosuppression in the infant, breastfeeding is generally contraindicated during and for a substantial period after treatment, and mothers should be counseled about alternative feeding options and the emotional impact of enforced weaning.

Plant Alkaloids and Natural Products

Mechanism of action
These agents primarily affect the mitotic spindle by interacting with microtubules, thereby disrupting mitosis in the M phase of the cell cycle.

Subgroups and examples

• Vinca alkaloids: Inhibit microtubule assembly.
• Vincristine: Frequently used in leukemias and lymphomas; peripheral neuropathy is the dose-limiting toxicity.
• Taxanes: Stabilize microtubules, prevent their depolymerization, and block mitosis.
• Paclitaxel: Used in breast, ovarian, pancreatic, and lung cancers; notable for significant neurotoxicity, myelosuppression, and hypersensitivity reactions requiring premedication.
• Topoisomerase I inhibitors: Inhibit topoisomerase I and cause DNA strand breaks.
• Topotecan and Irinotecan: Indicated for ovarian cancer, small cell lung cancer (SCLC), and colorectal cancer; diarrhea (especially early and late forms with irinotecan) and myelosuppression are key toxicities.

Major adverse effects
Important adverse effects include neurotoxicity (peripheral neuropathy with vinca alkaloids and taxanes), myelosuppression (particularly with taxanes and topotecan), alopecia, gastrointestinal disturbances (nausea, vomiting, diarrhea with irinotecan), myalgias and arthralgias (taxanes), bradycardia and hypotension (taxanes), and allergic reactions (taxanes).

Main contraindications
Severe pre-existing neuropathy (for vinca alkaloids and taxanes), severe myelosuppression, significant hepatic insufficiency (irinotecan), pregnancy, breastfeeding, and hypersensitivity are typical contraindications.

Lactation considerations
Because vinca alkaloids, taxanes, and topoisomerase inhibitors have narrow therapeutic indices and can cause profound neurotoxicity and myelosuppression, their use during breastfeeding is generally not compatible with safe lactation. In addition, taxanes often require repeated cycles, which prolongs the time during which breastfeeding must be avoided, making maintenance of milk supply difficult even with pumping strategies.

Tyrosine Kinase Inhibitors and Other Targeted Agents

Mechanism of action
Tyrosine kinase inhibitors (TKIs) and other molecularly targeted agents block specific signaling pathways critical for tumor cell proliferation, survival, angiogenesis, and metastasis. They act on defined molecular targets such as mutated kinases or receptors like the vascular endothelial growth factor (VEGF) receptor.

Examples

• Imatinib: Inhibits Bcr‑Abl tyrosine kinase in chronic myeloid leukemia (CML) and c‑KIT in gastrointestinal stromal tumors (GIST); it has transformed CML into a chronic manageable disease for many patients.
• Erlotinib and Gefitinib: EGFR tyrosine kinase inhibitors used in non-small cell lung cancer (NSCLC) with EGFR mutations.
• Sorafenib and Sunitinib: Multikinase inhibitors targeting, among others, VEGF receptors, with indications in renal cell carcinoma and hepatocellular carcinoma.

Major adverse effects
Adverse effects vary considerably depending on the target and specific drug, but commonly include skin reactions (papulopustular “acneiform” rash, dryness, pigmentary changes), diarrhea, hypertension, fatigue, stomatitis, and QT interval prolongation for some agents. Some TKIs have characteristic toxicities such as hypothyroidism with sunitinib.

Main contraindications
Severe hypersensitivity, significant drug–drug interactions (notably via CYP450), pregnancy, breastfeeding, and severe organ dysfunction (e.g. hepatic impairment for certain TKIs) are key contraindications.

Lactation considerations
TKIs often have prolonged half-lives, high oral bioavailability, and complex metabolism, which raises concern for clinically relevant exposure in breastfed infants and potential long-term developmental and carcinogenic risks. Given the paucity of robust lactation data and the availability of safer alternatives for most maternal indications, breastfeeding is usually discouraged during TKI therapy and for an appropriate post-treatment interval, with decisions individualized and based on updated, drug-specific guidelines.

Immunotherapeutic Agents

Mechanism of action
Immunotherapeutic agents activate or modulate the patient’s immune system to recognize and attack tumor cells. They include immune checkpoint inhibitors and monoclonal antibodies directed against tumor-associated antigens.

Subgroups and examples

• Immune checkpoint inhibitors (removing inhibitory “brakes” from T‑cells):
• Pembrolizumab and Nivolumab: Anti‑PD‑1 antibodies used in melanoma, NSCLC, renal cell carcinoma (RCC), Hodgkin lymphoma, and other malignancies.
• Ipilimumab: An anti‑CTLA‑4 antibody primarily used in melanoma.
• Monoclonal antibodies (mAbs) targeting specific tumor antigens:
• Rituximab: Anti‑CD20 mAb for B‑cell non‑Hodgkin lymphomas and chronic lymphocytic leukemia (CLL).
• Trastuzumab: Anti‑HER2 mAb for HER2‑positive breast and gastric cancers; associated with cardiotoxicity.

Major adverse effects
Immune-related adverse events (irAEs) can affect virtually any organ, including dermatitis, hepatitis, colitis, pneumonitis, and endocrine disorders such as thyroiditis or hypophysitis; fatigue, flu-like symptoms, and infusion reactions are also common. Management of irAEs often requires systemic corticosteroids or other immunosuppressants.

Main contraindications
Severe pre-existing autoimmune disease (relative contraindication), active infections, pregnancy (for most agents), hypersensitivity, and inability to manage potential irAEs are key limitations.

Lactation considerations
Monoclonal antibodies are large molecules and their transfer into milk and oral bioavailability in infants may be limited, but long-term immunomodulatory effects and lack of robust safety data make routine use during breastfeeding problematic in oncology. In practice, for high-dose, long-term oncologic immunotherapy, breastfeeding is usually avoided, and any off-label continuation of breastfeeding requires detailed, individualized risk–benefit counseling and careful monitoring.

Other Notes

Hormonal therapy
Hormonal therapy is used in hormone-sensitive tumors such as breast and prostate cancer and is not a classical “cytostatic” class but remains a cornerstone of oncologic treatment (e.g. tamoxifen, aromatase inhibitors, GnRH analogues, antiandrogens). Many hormonal agents have better-defined lactation data, yet some (such as tamoxifen) may still be incompatible with breastfeeding due to potential hormonal effects on the infant and suppression of lactation.

Combination therapy
In most cases, combinations of drugs from different classes are used to enhance efficacy, reduce resistance, and sometimes allow dose reduction of individual agents. From a lactation standpoint, combination regimens usually increase the overall risk to the breastfed infant, making safe breastfeeding during cytotoxic combination therapy extremely unlikely.

Personalized medicine
Molecularly targeted therapies and immunotherapies rely heavily on specific tumor biomarkers (mutations, protein expression, PD‑L1 status), enabling individualized treatment strategies. Similarly, lactation counseling in oncology should be individualized, using drug-specific pharmacokinetic data, infant factors (age, prematurity, comorbidities), and maternal priorities to balance oncologic efficacy and breastfeeding goals.